Add to Calendar 3/7/2019 8:00:00 AM 3/7/2019 10:00:00 AM Weathering the Storm: BD/Finance Considerations for Economic Downturn Last year Biotech index reached all-time high and the IPO market was red hot. Since then we saw a glimpse of market correction. There is no crystal ball to predict timing of the next economic downturn. But, in the dynamic global economy we should always be ready. How can you improve your company’s chances to endure and even thrive in an economic slowdown? Hear past experiences from Business Development and Finance executives who have “been there, done that” in the past. Leverage our panel’s knowledge regarding the possible moves one could take in a buoyant economy to prepare for the unexpected. Have your questions ready for this interactive forum. MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139
CEO, TScan Therapeutics
David Southwell is the Chief Executive Officer of TScan Therapeutics, a discovery-stage company focused on finding cognate antigen targets to specific T cell receptors (TCRs). Previously, Mr. Southwell served as President and Chief Executive Officer of Inotek Pharmaceuticals until its merger with Rocket Pharmaceuticals in January 2018, leading Inotek's IPO, two secondary offerings and the ultimate merger into Rocket. He was Executive Vice President, Chief Financial Officer of Human Genome Sciences until its 2012 merger with GlaxoSmithKline plc. Prior to Human Genome Sciences, Mr. Southwell served as Executive Vice President and Chief Financial Officer of Sepracor for fifteen years, and as an investment banker at Lehman Brothers. Mr. Southwell currently serves on the Board of Directors of PTC Therapeutics, Rocket Pharmaceuticals, Spero Therapeutics and TScan Therapeutics. Mr. Southwell received a B.A. from Rice University and an M.B.A. from the Tuck School at Dartmouth College, where he has served as head of the MBA Advisory Board and currently serves on the Board of Overseers.